SiO2 Medical Products and Sanaria Sign Agreement for Cryogenic Vials for PfSPZ Vaccine to Prevent Malaria

Malaria is a devastating disease of almost unfathomable impact, which according to the World Health Organization caused an estimated 429,000 deaths and 214 million clinical cases in 2015. "Our goal is the development, licensure and fielding of a vaccine to prevent malaria. We are excited to partner with SMP, because we share the same passion and determination. We are confident that SMP's agility, speed, and expertise will help us achieve our goal," said Stephen L. Hoffman, CEO of Sanaria.

SMP believes this partnership is an essential step in helping to combat this deadly disease. "SMP is humbled to have been selected by Sanaria as a partner in its fight against malaria. The development of Sanaria's highly effective vaccine promises hope for millions affected by this disease. With such a vital vaccine in its final clinical development stages, SMP has dedicated its world-class team to develop the ideal container to meet Sanaria's needs and timelines. We are confident that Sanaria's vaccine preserved in SMP's cryogenic vials will provide the optimal solution for delivering the vaccine to those in need," commented Brian Maurer, Sr. Vice President of SMP.